Advisors Preferred LLC Makes New Investment in Insulet Corporation $PODD

Advisors Preferred LLC bought a new position in Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,823 shares of the medical instruments supplier’s stock, valued at approximately $847,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Inspire Investing LLC lifted its position in Insulet by 299.5% during the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 3,088 shares in the last quarter. Gradient Investments LLC purchased a new position in Insulet during the second quarter valued at $17,429,000. Goldman Sachs Group Inc. lifted its position in Insulet by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after purchasing an additional 10,628 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Insulet by 55.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier’s stock valued at $1,376,000 after purchasing an additional 1,867 shares in the last quarter. Finally, Vident Advisory LLC purchased a new position in shares of Insulet in the first quarter valued at about $216,000.

Insulet Stock Up 1.8%

Shares of NASDAQ:PODD opened at $318.77 on Tuesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a market capitalization of $22.44 billion, a PE ratio of 96.89, a price-to-earnings-growth ratio of 2.64 and a beta of 1.40. The business has a 50 day simple moving average of $326.38 and a two-hundred day simple moving average of $308.18. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $353.50.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet’s quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Morgan Stanley restated an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Oppenheimer boosted their price objective on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Finally, Royal Bank Of Canada boosted their price objective on Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $352.11.

Insider Buying and Selling

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is currently owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.